OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
BURLINGTON, Mass., April 30, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, May 8, 2018. Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on business operations.
The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #2880817. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
